Description
Ponatinib · CAS 943319-70-8 · C29H27F3N6O. UNII 4340891KFS.
Identification
| CAS Registry Number | 943319-70-8 |
|---|
| PubChem CID | 24826799 |
|---|
| Molecular formula | C29H27F3N6O |
|---|
| IUPAC name | 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide |
|---|
| UNII (FDA) | 4340891KFS |
|---|
Computed Descriptors
| Molecular Weight | 532.6 |
|---|
| XLogP3 | 4.1 |
|---|
| Hydrogen Bond Donor Count | 1 |
|---|
| Hydrogen Bond Acceptor Count | 8 |
|---|
| Rotatable Bond Count | 6 |
|---|
| Exact Mass | 532.21984399 |
|---|
| Monoisotopic Mass | 532.21984399 |
|---|
| Topological Polar Surface Area | 65.8 |
|---|
| Heavy Atom Count | 39 |
|---|
| Formal Charge | 0 |
|---|
Physical description & handling notes
- Stable if stored as directed; avoid strong oxidizing agents
- Dangerous products of decomposition: thermal ecomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides.
- 2.77 and 7.8
- Most amides hydrolyze to acids extremely slowly at 25 °C and pH 7 with half-lives measured in centuries.
- Off-white to yellow powder. MW: 569.02. pKa1 = 2.77; pKa2 = 7.8. Solubility: 7790, 3.44, and 0.16 ug/mL in pH 1.7, 2.7, and 7.5 buffers /Ponatinib hydrochloride/
- Oral: Tablets, film-coated: 15 or 45 mg (of ponatinib) Iclusig (Ariad).
GHS Hazard Classification
| Reported hazard statements | H301 (100%), H311 (50%), H331 (50%), H372 (50%) |
|---|
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
H311 (50%): Toxic in contact with skin [Danger Acute toxicity, dermal]
Documented Uses
- Antineoplastic Agents; Protein Kinase Inhibitors
- Ponatinib is a tyrosine kinase receptor inhibitor that is used in the therapy of refractory chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome. Ponatinib is commonly associated with transient elevations in serum aminotransferase levels during treatment, but with only rare instances of clinically apparent acute liver injury.
- Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors
- Iclusig (ponatinib) is a kinase inhibitor indicated for the: Treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). /Included in US product label/
- Ponatinib may cause fetal harm; the drug has been shown to be embryotoxic and fetotoxic in animals. There are no adequate and well-controlled studies in pregnant women. Pregnancy should be avoided during therapy. If used during pregnancy or if the patient becomes pregnant while receiving ponatinib, the patient should be apprised of the potential fetal hazard.
- For more Drug Warnings (Complete) data for Ponatinib (22 total), please visit the HSDB record page.
Synonyms
PONATINIB; 943319-70-8; AP24534; AP 24534; AP-24534; ponatinibum; 4340891KFS; CHEBI:78543; DTXSID50241426; RefChem:58011; DTXCID50163917; L01XE24; 851-222-7; Ponatinib (AP24534); MFCD17215203; CHEMBL1171837
Frequently Asked Questions
What are the CAS number and molecular formula of Ponatinib?
CAS 943319-70-8; molecular formula C29H27F3N6O; molecular weight — g/mol.
What other names is Ponatinib known by?
PONATINIB, 943319-70-8, AP24534, AP 24534, AP-24534, ponatinibum.
Is Ponatinib classified as hazardous?
Hazard statements reported: H301, H311, H331, H372.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.
